FDA Removes Regulatory Overhang From Inhibikase Therapeutics Parkinson, Atrophy Program
The FDA lifted the full Clinical Hold on Inhibikase Therapeutics Inc’s (NASDAQ:IKT) IkT-148009, the company’s c-Abl inhibitor, in Multiple System…
Enanta Pharmaceuticals To Present New Data For EDP-235, Its 3CL Protease Inhibitor, In Development As An Oral, Once-Daily Treatment For COVID-19, At The 36th International Conference On Antiviral Research
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease
Mesoblast’s Lead Drug Candidate Goes Under FDA Priority Review For Bone Marrow Transplant Complications In Kids
Mesoblast Ltd (NASDAQ:MESO) rallied after the FDA agreed to review the company’s lead drug candidate, remestemcel-L, on a priority basis, more…
Sage Therapeutics & Biogen Reveal FDA Does Not Currently Plan To Convene Advisory Committee Meeting To Discuss NDA For Zuranolone In Treatment Of Major Depressive Disorder & Postpartum Depression
Sage Therapeutics, and Biogen announced that the U.S. Food and Drug Administration (FDA) notified the companies that the agency does not currently plan to convene an advisory committee meeting to discuss the
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Privately held-Covis Pharma, the maker of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth, said…
Reported Late Tuesday March 7, FDA Accepts Mesoblast’s Resubmission Of The Biologic License Application For Remestemcel-L In Children With Steroid-Refractory Acute Graft Versus Host Disease As A Complete Response And Sets Goal Date Of August 2, 2023
Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration's (FDA) Office of Therapeutic
FDA’s Regulatory Delay is The Reason For Novavax, Lucira Health’s Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb
‘Qualigen Peer-Reviewed Journal Article Out Titled “The Potent G-Quadruplex-Binding Compound QN-302 Downregulates S100p Gene Expression In Cells And In An In Vivo Model Of Pancreatic Cancer”‘
https://www.mdpi.com/1420-3049/28/6/2452
Abstract
The naphthalene diimide compound QN-302, designed to bind to G-quadruplex DNA sequences within the promoter regions of cancer-related genes, has high anti-proliferative
Dupixent Application For Treatment Of Chronic Spontaneous Urticaria In Adults And Adolescents Accepted For FDA Review
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
More than 300,000 people in the